How to Secure an Import Drug License in China: 2026 Guide

Article ID: CG360-PHARMA-GUID-007 | Knowledge Center: Pharmaceuticals | Last Updated: July 2026

1. Overview: The 2026 Import Drug Landscape

China’s pharmaceutical market was valued at over USD 280 billion in 2025, with imported drugs accounting for roughly 38% of hospital pharmaceutical spending despite representing only 12% of total approved drug SKUs. This stark ratio underscores both the premium position foreign drugs command and the regulatory hurdles that limit their numbers. For any overseas pharmaceutical company seeking to enter the world’s second-largest drug market in 2026, securing an Import Drug License from the National Medical Products Administration (NMPA) remains the single most consequential milestone.

This guide provides a complete, step-by-step walkthrough of the NMPA import drug registration process as it stands in mid-2026 — covering classification, document requirements, clinical trial expectations, timelines, costs, and accelerated pathways. Whether you are a mid-size European biotech launching your first oncology asset in Asia or a multinational with a portfolio of approved generics, the framework described here applies to all overseas-manufactured drugs seeking Chinese market access.

Remote China market entry support is now widely available through specialized regulatory consultancies, and this guide will show you exactly where to engage them for maximum leverage.

2. Regulatory Framework & Drug Classification

2.1 The NMPA and CDE

The National Medical Products Administration (NMPA) is the central regulatory authority for drugs, medical devices, and cosmetics in China. Drug registration is handled operationally by the Center for Drug Evaluation (CDE), an NMPA subordinate body that conducts the scientific and technical review of all drug applications. The key legal instruments governing import drug registration are:

• Drug Administration Law of the PRC (2019 revision) — the foundational statute.
• Drug Registration Regulation (NRD, effective July 1, 2020) — the primary implementing regulation.
• Implementation Rules for the Drug Registration Regulation — detailed procedural guidance.
• M4 Common Technical Document (CTD) Guidelines — mandatory dossier format adopted from ICH.

2.2 Drug Classification for Import Registration

Under the current NMPA classification system, drugs are categorized as follows:

The vast majority of import drug license applications fall under Class 5, subdivided into 5.1 (innovative) and 5.2 (generic). The distinction matters because clinical data requirements differ significantly between the two subcategories, as discussed in Section 6.

3. Required Documents & Dossier Preparation

Preparing the application dossier is the most time-intensive phase of the entire process, typically consuming 4 to 8 months. The dossier must follow the ICH M4 Common Technical Document (CTD) format, organized into five modules:

1. Module 1 (Administrative): Letter of authorization from the overseas manufacturer; power of attorney for the local agent; manufacturing license (GMP certificate issued by the competent authority of the manufacturing country); drug master file (DMF) declaration; Chinese business license of the applicant or local agent.
2. Module 2 (Summaries): Quality overall summary; nonclinical overview; clinical overview; benefit-risk assessment in the Chinese population context.
3. Module 3 (Quality): Complete drug substance and drug product information; specification and testing methods; stability data (ICH conditions, minimum 12 months room temperature and 6 months accelerated); impurity profiles; packaging and container closure system details; batch analysis for at least three commercial-scale batches.
4. Module 4 (Nonclinical): Pharmacology (primary and secondary pharmacodynamics, safety pharmacology); pharmacokinetics (ADME, toxicokinetics); toxicology (single-dose, repeated-dose, genotoxicity, carcinogenicity, reproductive toxicity, local tolerance). For drugs with prior foreign approval, existing nonclinical data are generally accepted subject to a CDE assessment of adequacy.
5. Module 5 (Clinical): Full clinical study reports from all phases; overseas clinical data package; Chinese bridging study or BE study report (if required); pediatric or special population data where applicable.

4. Step-by-Step Application Process

The complete import drug license application process proceeds through eight distinct stages. Below is the ordered sequence that every foreign applicant must follow in 2026:

1. Pre-submission strategy & dossier compilation (Months 1–4). Engage a qualified Chinese regulatory agent (mandatory for foreign applicants); classify the drug (Class 5.1 or 5.2); compile the CTD dossier in Chinese; secure notarized translations of all foreign-issued certificates. A pre-submission meeting with CDE is optional but strongly recommended for first-time applicants.
2. Formal submission & acceptance review (Month 5). Submit the application dossier to the CDE via the online registration system (acceptance. cde.org.cn). The CDE has 60 working days to conduct a form-and-content acceptance review. If the dossier is incomplete, the CDE issues a Notice of Supplementary Requirements, and the 60-day clock resets upon resubmission.
3. Technical review — standard track (Months 6–15). CDE assigns a review team of pharmacologists, chemists, and clinicians. Standard review takes up to 200 working days (approx. 9–10 calendar months). During this phase the CDE may issue one or more Questions for Supplementary Data; the applicant then has 4–8 months to respond, during which the review clock pauses.
4. Technical review — supplementary response (if applicable). This is the most common cause of timeline extension. Prepare and submit additional clinical data, quality data, or risk-management justification as requested. Responses that do not fully address CDE concerns will trigger additional rounds of questioning.
5. On-site inspection (Months 16–19). NMPA inspectors visit the overseas manufacturing site to verify GMP compliance and consistency between the dossier and actual production. This is a mandatory step for all Class 5 applications. Inspection scheduling depends on inspector availability, and foreign site visits are typically batched into two windows per year.
6. Sample testing (Months 19–22). NMPA-designated drug testing institutes (typically the National Institutes for Food and Drug Control, NIFDC) perform independent quality testing on three batches of the imported drug. The testing cycle is 60–90 working days.
7. Approval & certificate issuance (Month 22). If technical review, inspection, and sample testing all pass, CDE compiles a final review report. NMPA issues the Import Drug Registration Certificate within 20 working days. The certificate is valid for 5 years and is renewable.
8. Post-approval obligations (Ongoing). Submit annual reports to CDE; report any safety signals within 15 days; notify NMPA of any manufacturing changes (major changes require prior approval). Renewal application must be filed 6 months before certificate expiry.

5. Timeline & Cost Breakdown

5.1 Consolidated Timeline

5.2 Cost Estimates

The financial investment required to secure an import drug license in China is substantial. Budget figures are in 2026 market rates (USD):

• NMPA registration application fee: RMB 90,000–450,000 (~USD 12,500–62,500), depending on drug class and review complexity.
• CTD dossier preparation & translation: USD 50,000–150,000, including regulatory consulting and expert review.
• DMF preparation (drug substance): RMB 300,000–1,000,000 (~USD 42,000–140,000), highly dependent on API complexity.
• Clinical studies (CRO fees): RMB 5,000,000–20,000,000+ (~USD 700,000–2,800,000+) for a bridging BE study or Phase I PK trial in Chinese subjects.
• Regulatory consulting & local agent services: USD 50,000–200,000 for end-to-end support through to certificate issuance.
• On-site inspection travel & support: USD 30,000–80,000 per inspection event.

Total all-in costs typically range from USD 1.2 million to 4.5 million for a straightforward Class 5.2 generic, and from USD 3 million to 8 million+ for a Class 5.1 innovative drug requiring a bridging clinical study.

6. Clinical Trial Requirements for Import Drugs

Clinical data requirements are the make-or-break element of any import drug application. The NMPA accepts overseas clinical data under the Overseas Clinical Data Acceptance Policy, but with important conditions:

• Class 5.1 (innovative drugs approved abroad): If the drug has been approved in at least one major foreign jurisdiction (US, EU, Japan), the applicant may submit the existing overseas clinical trial data package. However, if there is evidence of racial sensitivity in pharmacokinetics, pharmacodynamics, or safety, the CDE will require a bridging study in a Chinese population. Factors assessed include: metabolic pathway polymorphisms (e.g., CYP2C9, CYP2C19), body weight distributions, dietary differences, and concurrent medication patterns in Chinese patients.
• Class 5.2 (generic drugs approved abroad): A bioequivalence (BE) study in a Chinese population is almost always mandatory. Single-dose, crossover BE studies in healthy Chinese volunteers are the standard design. The reference product must be the Chinese reference listed drug (RLD) if one exists; otherwise the overseas RLD is used with CDE approval.
• Racial sensitivity exemptions: For drugs with a wide therapeutic index, simple linear PK, and no evidence of ethnic differences in prior global studies, the CDE may grant an exemption from bridging studies. These exemptions require a detailed racial sensitivity analysis submitted as part of Module 2.5 of the CTD.

Since 2024, the CDE has increasingly accepted multi-regional clinical trial (MRCT) data that includes Chinese sites, provided the Chinese cohort size is statistically justified. For sponsors planning global Phase III programs, enrolling Chinese sites from the outset can eliminate the need for a separate bridging study and reduce the overall timeline by 6–12 months.

7. Accelerated Pathways & Strategic Considerations

7.1 Priority Review

Drugs that address an unmet medical need in China, or are intended for the treatment of life-threatening or seriously debilitating diseases for which no effective therapy exists in China, may qualify for priority review. This shortens the CDE technical review from 200 working days to 130 working days. Eligible indications include certain oncology subtypes, rare diseases (the number of recognized rare diseases in China expanded to 207 in 2025), and antimicrobial drugs on the national reserve list.

7.2 Conditional Approval

For drugs that demonstrate significant therapeutic promise based on surrogate endpoints (e.g., overall response rate in oncology, viral load reduction in infectious diseases), the NMPA may grant a conditional approval with a mandatory post-marketing confirmatory study commitment. This pathway can shave 6–12 months off the standard timeline and is increasingly used for cell and gene therapy products.

7.3 Urgent Clinical Need Exemption

Under the 2020 NRD, imported drugs that address a public health emergency or critical clinical shortage may be granted a temporary import license valid for 1–2 years, with a streamlined review process. This pathway was activated during the COVID-19 pandemic and has since been formally codified. In 2026, indications such as multidrug-resistant tuberculosis and certain pediatric oncology protocols are being flagged for this treatment.

7.4 Strategic Recommendations for 2026

• Engage a regulatory agent early. Foreign applicants are required to appoint a local agent registered with NMPA. The agent acts as the legal interface for all communications with CDE. Choose an agent with a track record in your therapeutic area.
• Invest in pre-submission consultations. CDE offers a voluntary pre-submission meeting (Type I meeting) for import drug applications. A single 90-minute meeting can identify critical data gaps and prevent months of back-and-forth during the review phase.
• Budget for supplementary data rounds. Industry data from 2024–2025 shows that over 70% of Class 5 applications receive at least one supplementary data request. Build both time and cost buffers into your project plan.
• Consider MRCT enrollment. Including Chinese sites in your global Phase III program from day one is the single most effective timeline compression strategy. It virtually eliminates the need for post-approval bridging studies and aligns with CDE’s stated preference for early China inclusion.
• Leverage remote support for market entry. Remote China market entry support through specialized regulatory consulting firms can reduce document preparation timelines by up to 40% compared to in-house efforts, particularly for translation, dossier formatting, and CDE submission portal navigation.

Where to Go From Here

Based on what you just read:

• Ready to act? Read [guide: How to Select a CRO in China: 2026 Guide for Foreign Pharma]
• Still comparing? See [comparison: NMPA Fast Track vs Standard Review for Import Drugs]
• Need numbers? Try [tool: China Drug Registration Timeline Estimator for Foreign Pharma]

How to Secure an Import Drug License in China: 2026 Guide — first published on China Gateway 360. Last updated: July 2026.